Purchase Order HHSN263201700332A

This contract was awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Acea Biosciences, Inc. for the acquisition of an xCELLigence RTCA-MP equipment package. The contract is a firm fixed-price purchase order with a potential value of $134,995.95. There was no set-aside designation for this award. Acea Biosciences is a life sciences company that provides specialized equipment, software, services, and expertise related to flow...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $32,593.00 on August 7, 2019, for in vitro testing of anti-cancer therapeutics using Xcelligence technology. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 6, 2019.</p>

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

This federal contract award was made by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Acea Biosciences, Inc. for the acquisition of an xCELLigence RTCA-MP equipment package. The $99,000.00 firm fixed-price purchase order does not have a set-aside designation. Acea Biosciences, a for-profit life sciences company, has received over 20 prior federal contract awards from agencies including the USDA, HHS, VA, and Navy to provide...

This one-year firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Child Health and Human Development to Acea Biosciences, Inc., a for-profit life sciences company that is a subsidiary of Agilent Technologies. The $8,705.70 contract is for an extended service warranty on a NovoCyte One laser system, which was likely procured by the NIH to support specialized research and testing. Acea Biosciences has...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $149,900.00 firm fixed-price purchase order contract to Acea Biosciences, Inc., a small business, for the supply of one xCELLigence RTCA CardioECR instrument or an equivalent brand name equal item. This specialized equipment is used for real-time measurement of cardiomyocyte contractility, viability, and electrical activity to support NCATS' research...

This federal contract was awarded by the Department of the Navy Bureau of Medicine and Surgery to Acea Biosciences, Inc., a subsidiary of Agilent Technologies, Inc. The $125,070.00 firm fixed price purchase order is for an XCELLIGENCE RTCA MP BUNDLE CAT# 00380601040, which is a real-time cell analysis system used in research laboratories. The contract does not have a set-aside designation. Acea Biosciences has received over 20 previous prime federal contracts from agencies like the Departments...

This is a firm fixed-price purchase order awarded by the Food and Drug Administration to Acea Biosciences, Inc., a small business, for a preventive maintenance agreement on the company's ACEA Biosciences/xCELLigence Real-Time Cell Analysis (RTCA) Dual Purpose (DP) unit. The ceiling value of the contract is $6,600.00 with a period of performance through September 12, 2024. Acea Biosciences, Inc. is a subsidiary of the parent company Agilent Technologies, Inc., a major provider of analytical...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for extended warranty services valued at $3,004.32 on February 20, 2020, with an ultimate completion date of February 28, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation. This purchase order was issued to de-obligate fiscal year 2020 expiring lines per NIH OALM communication 25-06.</p>